Seres Therapeutics (MCRB) said results from a phase 1b trial of SER-155 in people undergoing allogenic stem cell transplantation showed a "positive impact on biomarkers of systemic inflammation and immune homeostasis" compared with placebo.
The results back previous data showing that SER-155 "was associated with a significant reduction in bloodstream infections," the company said Thursday in a statement.
SER-155 is a live biotherapeutic designed to prevent infections in people undergoing allogenic stem cell transplantation to treat blood cancers, Seres said.
The company also said its cash runway was extended into Q1 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。